Back to top
more

Maravai LifeSciences (MRVI)

(Delayed Data from NSDQ)

$7.70 USD

7.70
1,260,217

+0.12 (1.58%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $7.70 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Options Traders Betting on a Big Move in Maravai LifeSciences (MRVI) Stock?

by Zacks Equity Research

Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.

Zynex Inc. (ZYXI) Q3 Earnings Match Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0% and 0.84%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

PetIQ (PETQ) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

PetIQ (PETQ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ZimVie Inc. (ZIMV) Stock Jumps 20.6%: Will It Continue to Soar?

by Zacks Equity Research

ZimVie Inc. (ZIMV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vapotherm (VAPO) delivered earnings and revenue surprises of -9.76% and 4.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q4 Earnings Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 2.94% and 0.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Vapotherm (VAPO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings Expected to Decline

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 Earnings Beat Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 15.63% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Maravai LifeSciences (MRVI) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Owens & Minor (OMI) Q2 Earnings Meet Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 0% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Maravai LifeSciences Holdings, Inc. (MRVI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie

by Zacks Equity Research

Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.

Tracey Ryniec headshot

5 Cheap Healthcare Stocks in 2022

by Tracey Ryniec

Looking for value stocks? Healthcare has been ignored over the last year.

Implied Volatility Surging for Maravai LifeSciences (MRVI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 25.58% and 6.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints

by Zacks Equity Research

Koninklijke Philips' (PHG) Q1 top- and bottom-line results reflect negative impact of supply chain constraints and consequences of the Respironics field action.

Wall Street Analysts See a 38% Upside in Maravai LifeSciences Holdings, Inc. (MRVI): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 38.1% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences

by Zacks Equity Research

Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.

Nilanjan Banerjee headshot

Sail Through the Choppy Market With These 4 Low-Beta Stocks

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.